SQRL-3R

GLP-3R (LY-3437943) – Triple-Agonist Research Compound

GLP-3R is a lab-made peptide that activates GLP-1, GIP, and glucagon receptors. Therefore, researchers study it for its effects on metabolic pathways. Moreover, studies show strong impacts on weight control, blood sugar balance, and metabolic health. In addition, its triple-action design works more broadly than single-pathway compounds. As a result, scientists see GLP-3R as a key candidate in obesity and diabetes research. Finally, this compound is intended only for laboratory studies and not for human use.

Why Researchers Choose GLP-3R

Multi-Receptor Action — Works on GLP-1, GIP, and glucagon receptors to target many pathways [Wikipedia; PeptideFiles; Synapse].
Strong Metabolic Results — Early trials showed large weight drops and better metabolic markers [NEJM; MDPI].
Clear Dose Response — Higher doses in studies led to stronger results [MDPI; PeptideFiles].
Better Tolerance Over Time — Initially, digestive side effects may appear; however, they often improve when the dose is increased more slowly [MDPI; NEJM].
Wide Research Use — Studied for obesity, type 2 diabetes, heart health, and liver disease [MDPI; Policy Lab].